Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH) that has been studied extensively in Russian clinical research for its potential neuroprotective and cognitive-enhancing properties. While it has been approved as a pharmaceutical agent in Russia since the 1990s, Western research remains limited, and investigators should approach the available literature with appropriate scientific rigor and an understanding of the regulatory landscape.
The Semax cognitive research peptide has attracted growing interest among neuroscience researchers and biohackers alike due to its unique mechanism of action and favorable safety profile observed in published studies. Originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax (Met-Glu-His-Phe-Pro-Gly-Pro, or MEHFPGP) is a heptapeptide fragment analog of ACTH(4-10) that has been the subject of hundreds of Russian-language publications spanning cognitive function, neuroprotection, and neurovascular health. This article provides a comprehensive overview of the existing research, practical considerations for investigators, and the broader context of Semax within the peptide research landscape.
What Is Semax? Structure and Origin
Semax was developed in the late 1980s by a team of scientists led by Nikolai Myasoedov at the Russian Academy of Sciences. The peptide is a synthetic analog of the ACTH(4-10) fragment — the biologically active portion of adrenocorticotropic hormone responsible for its nootropic effects, without the steroidogenic activity of full-length ACTH. The key innovation was the addition of a Pro-Gly-Pro tripeptide to the C-terminus of ACTH(4-7), which dramatically improved metabolic stability and extended the peptide’s half-life from seconds to several minutes.
In 1994, Semax received approval in Russia as a nasal spray formulation (marketed as a 0.1% solution) indicated for cognitive disorders, stroke recovery, and as a general nootropic. A higher-concentration formulation (1%) was later introduced for more acute neurological applications. It is important to note that Semax has not been approved by the FDA or EMA, and all research conducted outside of Russia should be treated as investigational.
Mechanisms of Action: How Semax May Influence Cognition
The cognitive research surrounding Semax points to multiple overlapping mechanisms, which partly explains its broad range of observed effects in preclinical and clinical studies. Understanding these pathways is critical for researchers designing protocols or interpreting results.
BDNF and Neurotrophic Signaling: One of the most consistently reported findings is that Semax upregulates brain-derived neurotrophic factor (BDNF) and its receptor TrkB. A 2006 study by Dolotov et al. demonstrated that intranasal Semax administration increased BDNF mRNA expression in the rat hippocampus and basal forebrain — regions critical for memory consolidation and learning. BDNF is widely recognized as a master regulator of synaptic plasticity and long-term potentiation.
Monoaminergic Modulation: Research by Eremin et al. (2005) showed that Semax influences serotonergic and dopaminergic systems, with observed increases in dopamine and serotonin turnover in the striatum and hippocampus. This may account for the anxiolytic and mood-stabilizing effects reported anecdotally by researchers.
Anti-Inflammatory and Neuroprotective Pathways: Semax has been investigated for its ability to modulate the expression of genes involved in the immune response and inflammation following cerebral ischemia. A transcriptomic study by Dergunova et al. (2018) identified significant alterations in genes related to the inflammatory cascade, suggesting a neuroprotective mechanism distinct from its neurotrophic activity.
NGF and Additional Neurotrophins: Beyond BDNF, evidence suggests that Semax may influence nerve growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF), further supporting its characterization as a broad-spectrum neurotrophic agent.
Summary of Key Research Findings
| Study / Author | Year | Model | Key Finding |
|---|---|---|---|
| Dolotov et al. | 2006 | Rat (in vivo) | Intranasal Semax increased BDNF mRNA in hippocampus and basal forebrain |
| Eremin et al. | 2005 | Rat (in vivo) | Modulated dopamine and serotonin metabolism in striatum and hippocampus |
| Dergunova et al. | 2018 | Rat (ischemia model) | Altered gene expression in inflammatory and immune response pathways post-stroke |
| Ashmarin et al. | 1995 | Human (clinical trial) | Improved attention and memory in patients with cognitive impairment (0.1% nasal spray) |
| Gusev & Skvortsova | 2001 | Human (clinical) | Reduced neurological deficit and improved recovery in acute ischemic stroke patients |
| Medvedev et al. | 2013 | Rat (in vivo) | Enhanced expression of neurotrophins NGF, BDNF, and TrkB in cerebral cortex |
Administration Routes and Dosing in Research
In published Russian clinical research, Semax is predominantly administered intranasally using a standardized nasal drop delivery system, typically at doses between 50–600 mcg per day (divided into 2–3 administrations). The 0.1% solution delivers approximately 50 mcg per drop, and most cognitive enhancement studies have used a range of 200–600 mcg daily for durations of 10–14 days.
In experimental research contexts, particularly outside of Russia where the nasal formulation is not commercially available, investigators may work with lyophilized Semax powder. Subcutaneous injection is occasionally referenced in preclinical literature. For researchers preparing injectable solutions, reconstitution with bacteriostatic water is standard practice to maintain sterility across multiple uses. Precise dosing is typically achieved using insulin syringes, and proper sterile technique — including the use of alcohol prep pads at injection sites — is essential for maintaining protocol integrity.
What You Will Need
Before beginning this protocol, researchers typically gather the following supplies: bacteriostatic water for reconstitution, insulin syringes for precise measurement, alcohol prep pads for sterile technique, and a sharps container for safe disposal. Proper peptide storage cases or a dedicated mini fridge help maintain compound integrity between uses. Semax is a relatively stable peptide when lyophilized, but once reconstituted it should be refrigerated at 2–8°C and used within a reasonable timeframe (typically within 3–4 weeks) to avoid degradation.
Semax Variants: N-Acetyl Semax and N-Acetyl Semax Amidate
Beyond the original Semax sequence, two modified variants are commonly encountered in the research peptide space. N-Acetyl Semax (NASA) features an acetyl group at the N-terminus, which is hypothesized to further improve metabolic stability and blood-brain barrier penetration. N-Acetyl Semax Amidate (NASA-Amidate) adds an amide group at the C-terminus in addition to the acetylation, theoretically offering the greatest resistance to enzymatic degradation.
While these analogs are popular among self-experimenters, it is worth noting that the vast majority of the published clinical literature — including the stroke recovery and cognitive enhancement trials — was conducted using standard Semax. The modified variants have minimal peer-reviewed data supporting their proposed advantages, and researchers should weigh the available evidence accordingly.
Track your peptide protocol for free
Log every dose, cost, weight change, and observation in one place. Free web app — no credit card needed.
Safety Profile and Observed Side Effects
One of the more notable aspects of the Semax literature is the consistently favorable safety profile reported across both animal and human studies. Russian clinical trials spanning thousands of patients have reported very few adverse events, with the most common being mild nasal irritation from the intranasal formulation. No significant hormonal disruptions have been documented — a meaningful distinction from full-length ACTH, which directly stimulates cortisol production.
That said, researchers should be mindful that the existing safety data comes predominantly from short-duration protocols (10–21 days). Long-term safety data is limited, and chronic BDNF upregulation carries theoretical concerns regarding neuroplasticity dysregulation. As with all investigational compounds, a cautious approach is warranted.
Complementary Research Tools and Supplements
Researchers investigating cognitive peptides like Semax often incorporate complementary compounds to support broader neurological health outcomes. Lion’s mane mushroom has its own body of peer-reviewed research on NGF stimulation and may serve as an interesting parallel or adjunct to Semax protocols. Omega-3 fish oil, particularly formulations high in DHA, supports neuronal membrane integrity and has well-established anti-inflammatory properties relevant to neuroprotection research. Additionally, some investigators use ashwagandha as a cortisol-modulating adaptogen, which may be useful for stress management during intensive research cycles. For researchers focused on long-term brain health, NMN (nicotinamide mononucleotide) or NAD+ precursors are increasingly studied for their role in cellular energy metabolism and age-related cognitive decline.
Where to Source
When sourcing research peptides like Semax, the most important criteria are verified purity, transparent testing, and consistent quality across batches. Reputable vendors provide third-party testing with certificates of analysis (COAs) — typically from HPLC and mass spectrometry — confirming identity and purity above 98%. We recommend EZ Peptides (ezpeptides.com) as a primary source, as they provide publicly available COAs for each batch and maintain rigorous quality control standards. Use code PEPSTACK for 10% off at EZ Peptides. Regardless of your vendor, always review the COA before beginning any protocol and verify that the molecular weight and amino acid sequence match the expected compound.
Frequently Asked Questions
Q: What is the difference between Semax and Selank?
A: Both are synthetic peptides developed at the Russian Academy of Sciences, but they are derived from different parent molecules and target different systems. Semax is an ACTH(4-10) analog primarily studied for cognitive enhancement and neuroprotection, while Selank is a tuftsin analog primarily researched for anxiolytic and immunomodulatory effects. Some researchers investigate them in combination, though published data on combined protocols is limited.
Q: Is Semax administered intranasally or via injection?
A: In published Russian clinical trials, Semax is almost exclusively administered intranasally. However, in research contexts where lyophilized peptide is reconstituted from powder, subcutaneous injection is sometimes used. The choice of administration route can affect bioavailability and onset, and researchers should select the route most appropriate for their study design.
Q: How should reconstituted Semax be stored?
A: Once reconstituted with bacteriostatic water, Semax should be stored in a refrigerator at 2–8°C (36–46°F). A dedicated peptide storage case or mini fridge helps ensure consistent temperature and reduces the risk of contamination. Lyophilized (unreconstituted) Semax can be stored at -20°C for extended periods. Avoid repeated freeze-thaw cycles with reconstituted solutions.
Q: Are there any known drug interactions with Semax?
A: The published literature does not report significant drug interactions, though the data is limited and comes primarily from Russian clinical settings. Given Semax’s influence on monoaminergic systems, theoretical caution may be warranted when combining it with serotonergic or dopaminergic medications. Researchers should always consult relevant pharmacological literature and a qualified professional before combining compounds.
This article is for research and informational purposes only. Nothing on PepStackHQ constitutes medical advice. Consult a qualified healthcare professional before beginning any research protocol.